Chairman/CEO Thomas A. Moore to Discuss Clinical Trial Progress
Place: Hard Rock Hotel, Hollywood, Florida | Date: June 7, 2010 |Time: 9:30 A.M. EDT
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Chairman/CEO Thomas A. Moore of Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, will present at the Noble Financial Sixth Annual Equity Conference at 9:30a.m. EDT on June 7, 2010 at the Hard Rock Hotel in Hollywood, Florida.
For those interested in participating in the webcast, please register at least 10 minutes prior to the start of the presentation to ensure timely access. You will need the SilverLight viewer (a free download from presentation link) to participate. In addition, the webcast and associated collateral material(s) will be archived on the Company’s website for 90 days following the event.
About Noble Financial
Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service investment banking boutique focused on small-cap, emerging growth companies. The company has offices in New York, Boston, New Jersey, St Louis and Boca Raton.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Conrad F. Mir, 732-545-1590
Diana Moore, 732-545-1590
KEYWORDS: United States North America Florida New Jersey
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical